Drugs /

montanide isa 720

Back to Drugs List

Overview

NCI Definition [1]:
A proprietary adjuvant, applicable for water-in-oil (W/O; 30/70 v/v) vaccine emulsion, with potential immunoadjuvant activity. Montanide ISA 720 is made of natural metabolizable non-mineral oil and a highly refined emulsifier from the mannide mono-oleate family; it is rapidly metabolized and eliminated, and may be used in various vaccines, including cancer vaccines. Upon administration, Montanide ISA 720 forms a depot at the injection site and is therefore capable of slowly releasing the antigen(s) from the injection site. This may result in enhanced cellular and humoral immune responses to the antigen vaccine.

Clinical Trials

View Clinical Trials for montanide isa 720

Montanide isa 720 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating montanide isa 720, 1 is phase 1 (1 open).

ER Expression, ER Positive, and HLA-A*02:01 Positive are the most frequent biomarker inclusion criteria for montanide isa 720 clinical trials.

Breast carcinoma is the most common disease being investigated in montanide isa 720 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Montanide Isa 720
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating montanide isa 720 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
montanide isa 720, montanide isa 720, isa 720
NCIT ID [1]:
C97330

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.